PDF(Pubmed)
Abstract：
UNASSIGNED: Acute systolic heart failure (ASHF) is one of the most serious complications of the acute coronary syndrome (ACS), and increases the likelihood of adverse clinical outcomes. It remains unclear whether the use of non-invasive ventilation (NIV) could improve symptoms and reduce mortality in patients with ASHF derived from ACS.
UNASSIGNED: Data on biological, clinical, and demographic factors, as well as therapy data, were collected from patients with ASHF in the cardiac department. A total of 1257 ACS patients with ASHF were included in the study. Patients were divided into two groups. The control group received standard oxygen therapy. The comparison group consisted of those who underwent NIV as part of their immediate care. During hospitalization and at follow-up, information on both groups was systematically compared.
UNASSIGNED: In comparison with the control group, mean 24-hour urine output was found to be significantly higher in the NIV group. A significant reduction in the duration of symptoms was observed among patients in the NIV group from the time of admission until relief of dyspnea. Heart rate, C-reactive protein, estimated glomerular filtration rate, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was also improved, compared with those in the control group. The NIV group was found to have a higher survival rate. NIV was independently related to all-cause mortality in 1-year follow-up (hazard ratio, 0.674; p = 0.045).
UNASSIGNED: Our study shows that NIV, as compared with standard oxygen therapy, has a beneficial impact on heart rate, metabolic balance, and relief of dyspnea in ACS patients with ASHF which results in reduced intubation rate, duration of in-hospital stay, and 1-year mortality.
UNASSIGNED: Data on biological, clinical, and demographic factors, as well as therapy data, were collected from patients with ASHF in the cardiac department. A total of 1257 ACS patients with ASHF were included in the study. Patients were divided into two groups. The control group received standard oxygen therapy. The comparison group consisted of those who underwent NIV as part of their immediate care. During hospitalization and at follow-up, information on both groups was systematically compared.
UNASSIGNED: In comparison with the control group, mean 24-hour urine output was found to be significantly higher in the NIV group. A significant reduction in the duration of symptoms was observed among patients in the NIV group from the time of admission until relief of dyspnea. Heart rate, C-reactive protein, estimated glomerular filtration rate, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was also improved, compared with those in the control group. The NIV group was found to have a higher survival rate. NIV was independently related to all-cause mortality in 1-year follow-up (hazard ratio, 0.674; p = 0.045).
UNASSIGNED: Our study shows that NIV, as compared with standard oxygen therapy, has a beneficial impact on heart rate, metabolic balance, and relief of dyspnea in ACS patients with ASHF which results in reduced intubation rate, duration of in-hospital stay, and 1-year mortality.
摘要：
■急性收缩性心力衰竭（ASHF）是急性冠状动脉综合征（ACS）最严重的并发症之一，并增加不良临床结局的可能性。目前尚不清楚使用无创通气（NIV）是否可以改善ACS引起的ASHF患者的症状并降低死亡率。
■生物数据，临床,和人口因素，以及治疗数据，从心脏部门的ASHF患者中收集。共有1257名患有ASHF的ACS患者被纳入研究。将患者分为两组。对照组接受标准氧疗。对照组由接受NIV作为其即时护理的一部分的人组成。住院期间和随访期间，系统比较了两组的信息.
■与对照组相比，发现NIV组的平均24小时尿量明显较高.从入院到呼吸困难缓解，NIV组患者的症状持续时间显着减少。心率,C反应蛋白,估计肾小球滤过率，脑钠肽N末端激素原（NT-proBNP）也得到改善，与对照组相比。发现NIV组具有较高的存活率。在1年的随访中，NIV与全因死亡率独立相关(风险比，0.674；p=0.045）。
■我们的研究表明，NIV，与标准氧疗相比，对心率有有益的影响，代谢平衡,和缓解ACS患者的呼吸困难与ASHF，导致降低插管率，住院时间，和1年死亡率。
■生物数据，临床,和人口因素，以及治疗数据，从心脏部门的ASHF患者中收集。共有1257名患有ASHF的ACS患者被纳入研究。将患者分为两组。对照组接受标准氧疗。对照组由接受NIV作为其即时护理的一部分的人组成。住院期间和随访期间，系统比较了两组的信息.
■与对照组相比，发现NIV组的平均24小时尿量明显较高.从入院到呼吸困难缓解，NIV组患者的症状持续时间显着减少。心率,C反应蛋白,估计肾小球滤过率，脑钠肽N末端激素原（NT-proBNP）也得到改善，与对照组相比。发现NIV组具有较高的存活率。在1年的随访中，NIV与全因死亡率独立相关(风险比，0.674；p=0.045）。
■我们的研究表明，NIV，与标准氧疗相比，对心率有有益的影响，代谢平衡,和缓解ACS患者的呼吸困难与ASHF，导致降低插管率，住院时间，和1年死亡率。
